Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

The star cancer immunotherapy missed an important endpoint during a study with small cell lung cancer.

Merck's Keytruda Misses an Important Lung Cancer Goal

Merck's (MRK) phase III first-line SCLC study fails to meet one of the two primary endpoints.  It signs an oncology collaboration with Taiho Pharmaceutical and Astex Pharmaceuticals.

Merck's Keytruda Misses One of Two Goals in Lung Cancer Study

Pfizer

Pfizer (PFE) and Merck KGaA's Bavencio meets the primary goal in a late-stage study evaluating it as a first-line maintenance therapy for metastatic urothelial carcinoma, a form of bladder cancer.

Pfizer/Merck KGaA's Bavencio Positive in Bladder Cancer Study

Merck & Co. MRK, +0.43% shares slipped in the extended session Monday after the drug maker said that its lung-cancer drug Keytruda did not meet one of its endpoints in a clinical study.

Merck stock slides as lung-cancer drug misses a study endpoint

Allergan

Novartis

Novartis AG, Merck & Co Inc and Allergan Plc were among companies that raised U.S. prices on more than 100 prescription medicines on Friday, bringing the tally to 445 drugs that will cost more in 2020, according to data analyzed by healthcare research firm 3 Axis Advisors.

Novartis, Merck and Allergan join those raising U.S. drug prices for 2020

Merck (NYSE: MRK) generates its revenue primarily from sales of pharmaceutical products. The company generated $18 billion in sales in the United States, accounting for over 40% of its total revenue in 2018.

How Much Revenue Does Merck Generate From The United States?

Amgen

Canopy Growth

Here are three of the best healthcare stocks to buy, as the sector is flashing a 'buy-the-dip' setup to kick off the New Year.

3 of the Best Healthcare Stocks to Buy in 2020

Bristol-Myers

Home Depot

NIKE

Texas Instruments

Bristol-Myers Squibb, Merck, The Home Depot, Texas Instruments, and Nike could be strong dividend plays into the new year.

Best Dividend Stocks for January 2020

GlaxoSmithKline

Medtronic

By Robert Ross 2019 was a good year for stocks. US stocks have rocketed 28% this year.

3 Ways to Play the Healthcare Surge

AstraZeneca

In what could be the final approval for the year, the FDA OK'ed a label expansion Monday for Lynparza, which is being co-developed by Merck & Co.

Merck-AstraZeneca's Lynparza Snags FDA Nod For Pancreatic Cancer

FUJIFILM Holdings Corp

Acushnet Hlds

Lithia Motors

Sally Beauty Hlds

These top-ranked industries stocks are witnessing positive earnings estimate revisions for 2020 and are likely to boost portfolio returns.

5 Stocks From Top-Ranked Industries Ready to Explode in 2020

AbbVie

Johnson & Johnson

The stock market continued its end of the year rally Friday as the three major indices all hit new intraday highs.

3 Dividend-Paying Large Cap Pharma Stocks to Consider for 2020

Merck’s (NYSE: MRK) stock price grew over 50% from around $56 levels in 2017 to around $84 in 2019, primarily driven by revenue growth and expansion of the P/E multiple. Merck’s stock price growth was higher than

What’s Fueling Merck’s Stock Price Growth?

Athene Holding Ltd. Class A

Disney

Diamondback Energy

Occidental Petroleum

What tips, screens and stocks were value investors most interested in in 2019? Here are the most popular podcasts of the year.

The 3 Most Popular Value Investor Podcasts of 2019

Eli Lilly

Teva Pharmaceutical

Keep in mind that short sellers betting against big pharma are taking on an added risk.

Big Pharma Short Sellers Get Selective

Best Buy

Prologis

The stock market rose to record highs again on Friday as part of a much longer and historic expansion in the US economy.

3 Income Stocks to Buy with Market at New Highs

Newlink Genetics

NewLink Genetics Corp. (NASDAQ: NLNK) and Merck & Co. Inc. (NYSE: MRK) shares made handy gains on Friday after it was announced that the U.S. Food and Drug Administration (FDA) has granted approval to Ervebo, the Zaire Ebola virus vaccine V920.

The First Ebola Vaccine Has Been Approved in the US

FDA grants approval to Merck's (MRK) Ervebo vaccine for active immunization of individuals 18 years and above to protect against Ebola virus disease caused by Zaire Ebola virus.

Merck's Ebola Vaccine Ervebo Gets Approval in United States

Installed Building Products

Intel

NuVasive

When a broker upgrades a stock, you can rely on their judgment. Nonetheless, you should also take into account few other factors to ensure steady returns.

Buy These 5 Stocks With Upgraded Broker Ratings for 2020

The FDA's ODAC votes in favor of Merck's (MRK) Keytruda for non-muscle invasive bladder cancer. The panel also backs Lynparza as a first-line maintenance monotherapy for pancreatic cancer.

FDA Panel Laps Up Merck's Keytruda & Lynparza for New Maladies

Pfizer and Merck are both primarily engaged in the pharmaceutical business. Pfizer generated $54 billion sales in 2018, while Merck garnered $42 billion.

How Does Pfizer’s Revenue And Other Key Metrics Compare With That of Merck?

ArQule

Merck's Latest $2.7-Billion Buy Of ArQule Brings About Precision Targeted And Diversified Approach To Cancer Therapy

Merck's Strong Pipeline Projects High Growth Potential

Which stock wins in a matchup between these two big drugmakers?

Better Buy: AbbVie vs Merck

Which of these two pharmaceutical giants is poised to produce healthier returns?

News for Merck Stock (MRK)